Qiagen Expands Dx Footprint by Acquiring Stake in Alacris, EyeSense
January 11, 2011
Qiagen Expands Dx Footprint by Acquiring Stake in Alacris, EyeSense
Alacris Theranostics is using whole-genome sequence analysis to develop individualized cancer therapies while EyeSense is developing ophthalmic diagnostic systems for glucose monitoring of diabetes patients.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.